Understanding and Overcoming Resistance to Selective FGFR Inhibitors across <i>FGFR2</i> -Driven Malignancies
At progression to FGFR inhibitors, FGFR2-driven malignancies are characterized by high intra- and interpatient molecular heterogeneity, particularly in cholangiocarcinoma. Resistance to FGFR inhibitors can be overcome by sequential, molecularly oriented treatment strategies across FGFR2-driven tumors.
Authors
- Fabrice André (ORCID: https://orcid.org/0000-0001-5795-8357)
- Francesco Facchinetti (ORCID: https://orcid.org/0000-0001-6313-6341)
- David Combarel (ORCID: https://orcid.org/0000-0003-2935-2782)
- Cristina Smolenschi (ORCID: https://orcid.org/0000-0002-7568-6196)
- Benjamin Besse (ORCID: https://orcid.org/0000-0001-5090-8189)
- Luc Friboulet (ORCID: https://orcid.org/0000-0002-1129-4978)
- Yohann Loriot (ORCID: https://orcid.org/0000-0002-8338-1739)
- Ken A. Olaussen (ORCID: https://orcid.org/0000-0002-3115-8914)
- Jean‐Yves Scoazec (ORCID: https://orcid.org/0000-0003-1604-6823)
- Santiago Ponce-Aix (ORCID: https://orcid.org/0000-0002-2289-4709)
- Floriane Brayé (ORCID: https://orcid.org/0009-0002-3527-6771)
- Rastislav Bahleda (ORCID: https://orcid.org/0009-0001-8245-0544)
- Lambros Tselikas (ORCID: https://orcid.org/0000-0002-8878-4916)
- Antoîne Italiano (ORCID: https://orcid.org/0000-0002-8540-5351)
- Stefan Michiels (ORCID: https://orcid.org/0000-0002-6963-2968)
- Rémy Barbé (ORCID: https://orcid.org/0009-0008-4643-4492)
- Catline Nobre
- Ludovic Bigot (ORCID: https://orcid.org/0009-0009-0820-5370)
- Damien Vasseur (ORCID: https://orcid.org/0000-0001-8787-1498)
- Antoine Hollebecque (ORCID: https://orcid.org/0000-0003-2869-7551)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Université de Bordeaux (FR)
- Inserm (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1834
- Citations
- 31
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 7.25
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Merck KGaA
- BeiGene
- Incyte
- Fondation Philanthropia
- Yuhan
- Relay Therapeutics
- Astellas Pharma
- Servier
- European Research Council
- Daiichi Sankyo Europe